Short leukocyte telomeres predict 25-year Alzheimer's disease incidence in non-APOE ε4-carriers.
Competing risks
Death
Dementia
Leukocyte telomere length
Risk factors
Time-to-event analysis
Vascular dementia
Journal
Alzheimer's research & therapy
ISSN: 1758-9193
Titre abrégé: Alzheimers Res Ther
Pays: England
ID NLM: 101511643
Informations de publication
Date de publication:
15 07 2021
15 07 2021
Historique:
received:
16
04
2021
accepted:
29
06
2021
entrez:
16
7
2021
pubmed:
17
7
2021
medline:
14
8
2021
Statut:
epublish
Résumé
Leukocyte telomere length (LTL) has been shown to predict Alzheimer's disease (AD), albeit inconsistently. Failing to account for the competing risks between AD, other dementia types, and mortality, can be an explanation for the inconsistent findings in previous time-to-event analyses. Furthermore, previous studies indicate that the association between LTL and AD is non-linear and may differ depending on apolipoprotein E (APOE) ε4 allele carriage, the strongest genetic AD predictor. We analyzed whether baseline LTL in interaction with APOE ε4 predicts AD, by following 1306 initially non-demented subjects for 25 years. Gender- and age-residualized LTL (rLTL) was categorized into tertiles of short, medium, and long rLTLs. Two complementary time-to-event models that account for competing risks were used; the Fine-Gray model to estimate the association between the rLTL tertiles and the cumulative incidence of AD, and the cause-specific hazard model to assess whether the cause-specific risk of AD differed between the rLTL groups. Vascular dementia and death were considered competing risk events. Models were adjusted for baseline lifestyle-related risk factors, gender, age, and non-proportional hazards. After follow-up, 149 were diagnosed with AD, 96 were diagnosed with vascular dementia, 465 died without dementia, and 596 remained healthy. Baseline rLTL and other covariates were assessed on average 8 years before AD onset (range 1-24). APOE ε4-carriers had significantly increased incidence of AD, as well as increased cause-specific AD risk. A significant rLTL-APOE interaction indicated that short rLTL at baseline was significantly associated with an increased incidence of AD among non-APOE ε4-carriers (subdistribution hazard ratio = 3.24, CI 1.404-7.462, P = 0.005), as well as borderline associated with increased cause-specific risk of AD (cause-specific hazard ratio = 1.67, CI 0.947-2.964, P = 0.07). Among APOE ε4-carriers, short or long rLTLs were not significantly associated with AD incidence, nor with the cause-specific risk of AD. Our findings from two complementary competing risk time-to-event models indicate that short rLTL may be a valuable predictor of the AD incidence in non-APOE ε4-carriers, on average 8 years before AD onset. More generally, the findings highlight the importance of accounting for competing risks, as well as the APOE status of participants in AD biomarker research.
Sections du résumé
BACKGROUND
Leukocyte telomere length (LTL) has been shown to predict Alzheimer's disease (AD), albeit inconsistently. Failing to account for the competing risks between AD, other dementia types, and mortality, can be an explanation for the inconsistent findings in previous time-to-event analyses. Furthermore, previous studies indicate that the association between LTL and AD is non-linear and may differ depending on apolipoprotein E (APOE) ε4 allele carriage, the strongest genetic AD predictor.
METHODS
We analyzed whether baseline LTL in interaction with APOE ε4 predicts AD, by following 1306 initially non-demented subjects for 25 years. Gender- and age-residualized LTL (rLTL) was categorized into tertiles of short, medium, and long rLTLs. Two complementary time-to-event models that account for competing risks were used; the Fine-Gray model to estimate the association between the rLTL tertiles and the cumulative incidence of AD, and the cause-specific hazard model to assess whether the cause-specific risk of AD differed between the rLTL groups. Vascular dementia and death were considered competing risk events. Models were adjusted for baseline lifestyle-related risk factors, gender, age, and non-proportional hazards.
RESULTS
After follow-up, 149 were diagnosed with AD, 96 were diagnosed with vascular dementia, 465 died without dementia, and 596 remained healthy. Baseline rLTL and other covariates were assessed on average 8 years before AD onset (range 1-24). APOE ε4-carriers had significantly increased incidence of AD, as well as increased cause-specific AD risk. A significant rLTL-APOE interaction indicated that short rLTL at baseline was significantly associated with an increased incidence of AD among non-APOE ε4-carriers (subdistribution hazard ratio = 3.24, CI 1.404-7.462, P = 0.005), as well as borderline associated with increased cause-specific risk of AD (cause-specific hazard ratio = 1.67, CI 0.947-2.964, P = 0.07). Among APOE ε4-carriers, short or long rLTLs were not significantly associated with AD incidence, nor with the cause-specific risk of AD.
CONCLUSIONS
Our findings from two complementary competing risk time-to-event models indicate that short rLTL may be a valuable predictor of the AD incidence in non-APOE ε4-carriers, on average 8 years before AD onset. More generally, the findings highlight the importance of accounting for competing risks, as well as the APOE status of participants in AD biomarker research.
Identifiants
pubmed: 34266503
doi: 10.1186/s13195-021-00871-y
pii: 10.1186/s13195-021-00871-y
pmc: PMC8283833
doi:
Substances chimiques
Apolipoprotein E4
0
Apolipoproteins E
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
130Informations de copyright
© 2021. The Author(s).
Références
Ann Neurol. 2006 Aug;60(2):174-80
pubmed: 16685698
J Gerontol A Biol Sci Med Sci. 2012 Apr;67(4):330-5
pubmed: 22016362
J Gerontol A Biol Sci Med Sci. 2016 Aug;71(8):1069-73
pubmed: 27091133
Lab Invest. 2000 Nov;80(11):1739-47
pubmed: 11092534
Lancet Neurol. 2021 Jan;20(1):68-80
pubmed: 33340485
Ageing Res Rev. 2018 Dec;48:11-20
pubmed: 30254001
Aging (Albany NY). 2020 Mar 3;12(5):4407-4423
pubmed: 32126022
J Gerontol A Biol Sci Med Sci. 2021 May 22;76(6):955-963
pubmed: 33367599
Arch Neurol. 2012 Oct;69(10):1332-9
pubmed: 22825311
Alzheimers Res Ther. 2017 Aug 9;9(1):60
pubmed: 28793924
Med Care. 2010 Jun;48(6 Suppl):S96-105
pubmed: 20473207
Transl Psychiatry. 2017 Apr 18;7(4):e1100
pubmed: 28418400
Bone Marrow Transplant. 2020 Apr;55(4):675-680
pubmed: 31576022
Circulation. 2016 Feb 9;133(6):601-9
pubmed: 26858290
J Neurol Sci. 2010 Dec 15;299(1-2):108-11
pubmed: 20709332
J Neural Transm (Vienna). 2017 Jul;124(7):809-819
pubmed: 28393276
Alzheimers Dement (N Y). 2019 Dec 09;5:883-890
pubmed: 31890852
Genetics. 2015 Aug;200(4):1061-72
pubmed: 26092717
Exp Gerontol. 2012 Feb;47(2):179-82
pubmed: 22210159
PLoS One. 2012;7(4):e34292
pubmed: 22506016
Cell Rep. 2019 Apr 23;27(4):1293-1306.e6
pubmed: 31018141
Biochem Biophys Res Commun. 2007 Jun 22;358(1):215-8
pubmed: 17481586
Nucleic Acids Res. 2002 May 15;30(10):e47
pubmed: 12000852
Aging Cell. 2015 Dec;14(6):1003-13
pubmed: 26238505
Stat Med. 2017 Nov 30;36(27):4391-4400
pubmed: 28913837
Neurobiol Aging. 2012 Feb;33(2):335-44
pubmed: 20395015
Alzheimers Res Ther. 2020 Sep 26;12(1):117
pubmed: 32979926
JAMA Netw Open. 2020 Feb 5;3(2):e200023
pubmed: 32101305
Neurobiol Aging. 2011 Nov;32(11):2055-60
pubmed: 20031273
J Alzheimers Dis. 2020;73(2):707-714
pubmed: 31839608
Nat Rev Neurol. 2019 Sep;15(9):501-518
pubmed: 31367008
Brain. 2011 Jul;134(Pt 7):2044-56
pubmed: 21672962
Mech Ageing Dev. 2014 Nov-Dec;141-142:64-9
pubmed: 25454987
Neuropsychology. 2006 Nov;20(6):645-57
pubmed: 17100509
Neurology. 2020 Mar 10;94(10):436-448
pubmed: 32047067
Neurobiol Aging. 2003 Jan-Feb;24(1):77-84
pubmed: 12493553
Circulation. 2020 Mar 3;141(9):e139-e596
pubmed: 31992061
Oncotarget. 2017 Oct 31;8(62):104706-104716
pubmed: 29285207
Ann Neurol. 2006 Aug;60(2):181-7
pubmed: 16807921
Dement Geriatr Cogn Disord. 2011;31(1):20-30
pubmed: 21124030
BMC Med. 2017 Mar 6;15(1):48
pubmed: 28260527
Philos Trans R Soc Lond B Biol Sci. 2018 Mar 5;373(1741):
pubmed: 29335375
Science. 2015 Dec 4;350(6265):1193-8
pubmed: 26785477
BMJ. 2014 Jul 08;349:g4373
pubmed: 25005709
JAMA Neurol. 2014 Jul 1;71(7):921-3
pubmed: 25023551
Cell. 2019 Oct 3;179(2):312-339
pubmed: 31564456
Ann Neurol. 2021 Jan;89(1):54-65
pubmed: 32996171
J Clin Epidemiol. 2013 Jun;66(6):648-53
pubmed: 23415868
Ann Transl Med. 2018 Aug;6(16):325
pubmed: 30364028
Exp Gerontol. 2017 Nov;98:143-147
pubmed: 28827085
Nat Rev Mol Cell Biol. 2010 Mar;11(3):171-81
pubmed: 20125188
Lancet Neurol. 2016 Jul;15(8):857-868
pubmed: 27302364
Front Aging Neurosci. 2016 Jul 12;8:171
pubmed: 27462267
Ann Transl Med. 2017 Feb;5(3):47
pubmed: 28251126
JAMA Neurol. 2014 Oct;71(10):1247-54
pubmed: 25090243
PLoS One. 2019 Jul 29;14(7):e0219668
pubmed: 31356640
Eur J Nutr. 2020 Feb;59(1):119-126
pubmed: 30649596
Physiol Rev. 2008 Apr;88(2):557-79
pubmed: 18391173
Alzheimers Res Ther. 2020 Nov 4;12(1):141
pubmed: 33148345
Annu Rev Public Health. 2019 Apr 1;40:65-84
pubmed: 30642228
Ageing Res Rev. 2020 Dec;64:101184
pubmed: 32992046
Mol Psychiatry. 2020 Nov;25(11):2942-2951
pubmed: 30514930
Neurobiol Aging. 2010 Apr;31(4):719-20
pubmed: 18599157
Nat Commun. 2020 Feb 3;11(1):667
pubmed: 32015339